| URN | urn:agi-llid:1906 |
|---|---|
| Total Entities | 0 |
| Connectivity | 3260 |
| Name | Edn1 |
| Description | endothelin 1 |
| Notes | The protein encoded by this gene is proteolytically processed to release a secreted peptide termed endothelin 1. This peptide is a potent vasoconstrictor and is produced by vascular endothelial cells. Endothelin 1 also can affect the central nervous system. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq] |
| Ariadne Ontology | Neuromodulator |
|---|---|
| Secreted proteins | |
| Biofluids assayable substances |
| GO Molecular Function | receptor binding |
|---|---|
| hormone activity | |
| cytokine activity | |
| endothelin A receptor binding | |
| endothelin B receptor binding |
| GO Cellular Component | extracellular region |
|---|---|
| cytoplasm | |
| extracellular space |
| GO Biological Process | cell growth |
|---|---|
| positive regulation of mitosis | |
| cell-cell signaling | |
| rhythmic excitation | |
| positive regulation of chemokine-mediated signaling pathway | |
| protein kinase C deactivation | |
| positive regulation of JUN kinase activity | |
| positive regulation of MAP kinase activity | |
| negative regulation of hormone secretion | |
| positive regulation of hormone secretion | |
| cell surface receptor signaling pathway | |
| intracellular protein kinase cascade | |
| calcium-mediated signaling | |
| inositol phosphate-mediated signaling | |
| phosphatidylinositol 3-kinase cascade | |
| G-protein coupled receptor signaling pathway | |
| phospholipase D-activating G-protein coupled receptor signaling pathway | |
| protein kinase C-activating G-protein coupled receptor signaling pathway | |
| positive regulation of receptor biosynthetic process | |
| positive regulation of nitric oxide biosynthetic process | |
| negative regulation of cellular protein metabolic process | |
| negative regulation of transcription from RNA polymerase II promoter | |
| negative regulation of cAMP biosynthetic process | |
| negative regulation of smooth muscle cell apoptotic process | |
| positive regulation of cell proliferation | |
| positive regulation of smooth muscle cell proliferation | |
| positive regulation of cell migration | |
| positive regulation of endothelial cell migration | |
| positive regulation of neutrophil chemotaxis | |
| positive regulation of sarcomere organization | |
| neural crest cell development | |
| leukocyte activation | |
| peptide hormone secretion | |
| superoxide anion generation | |
| membrane depolarization | |
| elevation of cytosolic calcium ion concentration | |
| elevation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway | |
| neutrophil chemotaxis | |
| cellular response to interleukin-1 | |
| cellular response to tumor necrosis factor | |
| response to drug | |
| response to amino acid stimulus | |
| response to lipopolysaccharide | |
| response to testosterone stimulus | |
| response to nicotine | |
| response to hypoxia | |
| negative regulation of blood coagulation | |
| negative regulation of nitric-oxide synthase biosynthetic process | |
| positive regulation of renal sodium excretion | |
| positive regulation of heart rate | |
| positive regulation of cardiac muscle hypertrophy | |
| positive regulation of smooth muscle contraction | |
| positive regulation of odontogenesis | |
| regulation of vasoconstriction | |
| regulation of sensory perception of pain | |
| positive regulation of prostaglandin-endoperoxide synthase activity | |
| middle ear morphogenesis | |
| patterning of blood vessels | |
| skeletal system development | |
| heart development | |
| cartilage development | |
| in utero embryonic development | |
| dorsal-ventral pattern formation | |
| blood vessel morphogenesis | |
| multicellular organismal aging | |
| respiratory gaseous exchange | |
| sensory perception of pain | |
| regulation of systemic arterial blood pressure by endothelin | |
| artery smooth muscle contraction | |
| vein smooth muscle contraction | |
| regulation of blood vessel size | |
| vasoconstriction | |
| positive regulation of urine volume | |
| maternal process involved in parturition | |
| body fluid secretion | |
| histamine secretion | |
| epithelial fluid transport | |
| glucose transport | |
| nitric oxide transport | |
| prostaglandin biosynthetic process | |
| positive regulation of cell size | |
| regulation of blood pressure | |
| regulation of pH |
| Pathway | EndothelinRb -> AP-1/CREB/ELK-SRF signaling |
|---|---|
| EndothelinRa -> AP-1/CREB signaling | |
| Cyclosporine-Induced Nephrotoxicity | |
| TGFB1-TGFBR2 Expression Targets | |
| INHBA-ACVR2/ACVR1 Expression Targets | |
| TLR4/NF-kB/IRF Expression Targets | |
| TLR1/2/6 Expression Targets | |
| ICAM1 Expression Targets | |
| IL15 Expression Targets | |
| IL2 Expression Targets | |
| CTF1 Expression Targets | |
| Erythropoietin/STAT Expression Targets | |
| Erythropoietin/ELK-SRF Expression Targets | |
| Erythropoietin/NF-kB Expression Targets | |
| CSF2/NF-kB Expression Targets | |
| IFNG-IFNR Expression Targets | |
| Leptin/ELK-SRF Expression Targets | |
| Leptin/STAT Expression Targets | |
| EGF/HIF1A Expression Targets | |
| VEGFA/CTNNB/CTNND Expression Targets | |
| Erythropoietin/AP-1/MYC/CREB Expression Targets | |
| PGF/AP-1/CREB/CREBBP/MYC Expression Targets | |
| F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets | |
| F2 -> STAT1/NF-kB Expression Targets | |
| PLG -> AP-1/CREB/ELK-SRF/SP1 Expression Targets | |
| PLG -> STAT1/NF-kB Expression Targets | |
| Epinephrine/Gq Expression Targets | |
| Prostaglandin F Expression Targets | |
| AVP/Gq -> STAT Expression Targets | |
| AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets | |
| AVP/Gq -> CREB/ELK-SRF/AP-1/EGR Expression Targets | |
| TAC1 Expression Targets | |
| Epinephrine/Gs Expression Targets | |
| Noradrenaline/Gs Expression Targets | |
| AVP/Gs -> STAT Expression Targets | |
| AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets | |
| Noreadrenaline/Gq Expression Targets | |
| EDN1 Expression Targets | |
| EDN3 Expression Targets | |
| HGF/STAT Expression Targets | |
| Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| Insulin/STAT Expression Targets | |
| INHBA-ACVR2/BMPR Expression Targets | |
| TGFB1-TGFBR1 Expression Targets | |
| TNF/NF-kB Expression Targets | |
| PAF Expression Targets | |
| AGT/CREB Expression Targets | |
| AGT/STAT Expression Targets | |
| EGF/AP-1/ATF Expression Targets | |
| EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| EGF/MEF/MYOD/NFATC Expression Targets | |
| EGF/STAT Expression Targets | |
| HGF/AP-1/CREB/ELK-SRF/MYC Expression Targets | |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | |
| Insulin/MEF/MYOD Expression Targets | |
| LPA Expression Targets | |
| PAF/Gq -> AP-1/ATF1/CREB/ERK-SRF Expression Targets | |
| PDGF/AP-1/CREB/CREBBP/MYC Expression Targets | |
| PDGF/STAT Expression Targets | |
| TGFB1-ACVRL1 Expression Targets | |
| TGFB1-TGFBR1/AP-1 Expression Targets | |
| TNF/AP-1 Expression Targets | |
| IL1B Expression Targets | |
| EGF/CTNN Expression Targets | |
| drug-gene, gene-chemical, gene-gene interaction pathway | |
| losartan_expanded2 | |
| losartan_expanded3 | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway | |
| losartan-gene, gene-chemical, gene-gene interaction pathway |
| Group | Neuromodulator |
|---|---|
| cell growth | |
| positive regulation of mitosis | |
| cell-cell signaling | |
| rhythmic excitation | |
| positive regulation of chemokine-mediated signaling pathway | |
| protein kinase C deactivation | |
| positive regulation of JUN kinase activity | |
| positive regulation of MAP kinase activity | |
| negative regulation of hormone secretion | |
| positive regulation of hormone secretion | |
| cell surface receptor signaling pathway | |
| intracellular protein kinase cascade | |
| calcium-mediated signaling | |
| inositol phosphate-mediated signaling | |
| phosphatidylinositol 3-kinase cascade | |
| G-protein coupled receptor signaling pathway | |
| phospholipase D-activating G-protein coupled receptor signaling pathway | |
| protein kinase C-activating G-protein coupled receptor signaling pathway | |
| positive regulation of receptor biosynthetic process | |
| positive regulation of nitric oxide biosynthetic process | |
| negative regulation of cellular protein metabolic process | |
| negative regulation of transcription from RNA polymerase II promoter | |
| negative regulation of cAMP biosynthetic process | |
| negative regulation of smooth muscle cell apoptotic process | |
| positive regulation of cell proliferation | |
| positive regulation of smooth muscle cell proliferation | |
| positive regulation of cell migration | |
| positive regulation of endothelial cell migration | |
| positive regulation of neutrophil chemotaxis | |
| positive regulation of sarcomere organization | |
| neural crest cell development | |
| leukocyte activation | |
| peptide hormone secretion | |
| superoxide anion generation | |
| membrane depolarization | |
| elevation of cytosolic calcium ion concentration | |
| elevation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway | |
| neutrophil chemotaxis | |
| cellular response to interleukin-1 | |
| cellular response to tumor necrosis factor | |
| response to drug | |
| response to amino acid stimulus | |
| response to lipopolysaccharide | |
| response to testosterone stimulus | |
| response to nicotine | |
| response to hypoxia | |
| negative regulation of blood coagulation | |
| negative regulation of nitric-oxide synthase biosynthetic process | |
| positive regulation of renal sodium excretion | |
| positive regulation of heart rate | |
| positive regulation of cardiac muscle hypertrophy | |
| positive regulation of smooth muscle contraction | |
| positive regulation of odontogenesis | |
| regulation of vasoconstriction | |
| regulation of sensory perception of pain | |
| positive regulation of prostaglandin-endoperoxide synthase activity | |
| middle ear morphogenesis | |
| patterning of blood vessels | |
| skeletal system development | |
| heart development | |
| cartilage development | |
| in utero embryonic development | |
| dorsal-ventral pattern formation | |
| blood vessel morphogenesis | |
| multicellular organismal aging | |
| respiratory gaseous exchange | |
| sensory perception of pain | |
| regulation of systemic arterial blood pressure by endothelin | |
| artery smooth muscle contraction | |
| vein smooth muscle contraction | |
| regulation of blood vessel size | |
| vasoconstriction | |
| positive regulation of urine volume | |
| maternal process involved in parturition | |
| body fluid secretion | |
| histamine secretion | |
| epithelial fluid transport | |
| glucose transport | |
| nitric oxide transport | |
| prostaglandin biosynthetic process | |
| positive regulation of cell size | |
| regulation of blood pressure | |
| regulation of pH | |
| receptor binding | |
| hormone activity | |
| cytokine activity | |
| endothelin A receptor binding | |
| endothelin B receptor binding | |
| extracellular region | |
| cytoplasm | |
| extracellular space | |
| Secreted proteins | |
| Biofluids assayable substances |
| MedScan ID | 1906 |
|---|
| Hugo ID | 3176 |
|---|
| Human chromosome position | 6p24.1 |
|---|
| LocusLink ID | 1906 |
|---|---|
| 13614 | |
| 24323 |
| Alias | ET1 |
|---|---|
| PPET1 | |
| HDLCQ7 | |
| endothelin-1 | |
| preproendothelin-1 | |
| ET-1 | |
| preproET | |
| preproendothelin | |
| ET-1 protein | |
| OTTHUMP00000039245 | |
| ET-1 mRNA | |
| OTTHUMP00000016038 | |
| EDN I | |
| ET I protein | |
| ET I | |
| endothelin I | |
| endothelin 1 | |
| EDN1 | |
| ET-1 gene |
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| OMIM ID | 131240 |
|---|
| Unigene ID | Hs.511899 |
|---|---|
| Hs.713645 | |
| Mm.14543 | |
| Rn.10918 |
| KEGG ID | hsa:1906 |
|---|---|
| mmu:13614 | |
| rno:24323 |
| Swiss-Prot Accession | P05305 |
|---|---|
| Q6FH53 | |
| P22387 | |
| Q544E0 | |
| P22388 | |
| P70203 | |
| P97338 | |
| Q96DA1 | |
| Q9JLX8 |
| GO ID | 0005125 |
|---|---|
| 0031707 | |
| 0031708 | |
| 0005179 | |
| 0007186 | |
| 0014824 | |
| 0007589 | |
| 0019722 | |
| 0051216 | |
| 0016049 | |
| 0007166 | |
| 0007267 | |
| 0071347 | |
| 0071356 | |
| 0009953 | |
| 0007204 | |
| 0051482 | |
| 0042045 | |
| 0015758 | |
| 0007507 | |
| 0001821 | |
| 0001701 | |
| 0048016 | |
| 0007243 | |
| 0045321 | |
| 0060137 | |
| 0051899 | |
| 0042474 | |
| 0010259 | |
| 0030195 | |
| 0030818 | |
| 0032269 | |
| 0046888 | |
| 0051771 | |
| 0034392 | |
| 0000122 | |
| 0014032 | |
| 0030593 | |
| 0030185 | |
| 0001569 | |
| 0030072 | |
| 0014065 | |
| 0031583 | |
| 0043507 | |
| 0043406 | |
| 0010613 | |
| 0030335 | |
| 0008284 | |
| 0045793 | |
| 0070101 | |
| 0010595 | |
| 0010460 | |
| 0046887 | |
| 0045840 | |
| 0090023 | |
| 0045429 | |
| 0042482 | |
| 0060585 | |
| 0010870 | |
| 0035815 | |
| 0060298 | |
| 0048661 | |
| 0045987 | |
| 0035810 | |
| 0001516 | |
| 0042313 | |
| 0007205 | |
| 0006885 | |
| 0051930 | |
| 0003100 | |
| 0019229 | |
| 0007585 | |
| 0043200 | |
| 0042493 | |
| 0001666 | |
| 0032496 | |
| 0035094 | |
| 0033574 | |
| 0043179 | |
| 0019233 | |
| 0042554 | |
| 0042310 | |
| 0014826 | |
| 0005737 | |
| 0005576 | |
| 0005615 | |
| 0005102 | |
| 0048514 | |
| 0008217 | |
| 0050880 | |
| 0001501 | |
| 0030146 | |
| 0030147 |
| PIR ID | JN0125 |
|---|---|
| S63538 | |
| A36517 |
| Swiss-Prot ID | EDN1_RAT |
|---|---|
| EDN1_MOUSE | |
| EDN1_HUMAN | |
| Q544E0_MOUSE | |
| Q6FH53_HUMAN |
| Cell Localization | Secreted |
|---|---|
| Extracellular |
| IPI ID | IPI00206210 |
|---|---|
| IPI00127462 | |
| IPI00008327 | |
| IPI00743618 |
| Mouse chromosome position | 13 26.0 cM |
|---|
| Rat chromosome position | 17p12 |
|---|
| Homologene ID | 1476 |
|---|
| MGI ID | 95283 |
|---|
| RGD ID | 2532 |
|---|
| Primary Cell Localization | Extracellular |
|---|